Publications by authors named "Muhammed Shiraz Moosa"
Article Synopsis
- HIV-associated tuberculosis (TB) leads to high mortality rates, especially in severely ill hospitalized patients, prompting this study to evaluate enhanced treatments.
- The study assesses the effectiveness and safety of high-dose rifampicin combined with levofloxacin and the use of corticosteroids for reducing early mortality in HIV-positive patients with disseminated TB.
- A phase III trial design tests these interventions against standard treatments, focusing on all-cause mortality and safety metrics over various timelines.
Aim: Serum microRNA-122 (miR-122) is a novel biomarker for drug-induced liver injury, with good sensitivity in the early diagnosis of paracetamol-induced liver injury. We describe miR-122 concentrations in participants with antituberculosis drug-induced liver injury (AT-DILI). We explored the relationship between miR-122 and alanine aminotransferase (ALT) concentrations and the effect of N-acetylcysteine (NAC) on miR-122 concentrations.
View Article and Find Full Text PDFBackground: There are limited data on the outcomes of rechallenge with anti-tuberculosis therapy (ATT) following anti-tuberculosis drug-induced liver injury (AT-DILI) in a high HIV prevalence setting.
Objectives: To describe the outcomes of rechallenge with first-line ATT.
Method: Hospitalised participants with AT-DILI who were enrolled into a randomised controlled trial of N-acetylcysteine in Cape Town, South Africa, were followed up until completion of ATT rechallenge.
Background: Liver injury is a common complication of anti-tuberculosis therapy. N-acetylcysteine (NAC) used in patients with paracetamol toxicity with limited evidence of benefit in liver injury due to other causes.
Methods: We conducted a randomized, double-blind, placebo-controlled trial to assess the efficacy of intravenous NAC in hospitalized adult patients with anti-tuberculosis drug-induced liver injury (AT-DILI).